Neurocrine Q2 Beat Drives Analyst Target Hikes, Pipeline Expansion
NBIX sits 37% above its 52-week low of $122.138 on elevated volume (3.6× avg).
Summary
Neurocrine's Q2 results, already reported, are now fueling analyst upgrades with price targets raised to $196–$249, signaling strong conviction in the Ingrezza franchise and pipeline. The company also disclosed operational expansions—hiring, a new biologics campus, and multiple clinical starts—including positive Phase 3 CRENESSITY data. These moves broaden the growth narrative beyond the core tardive dyskinesia drug. The raised Ingrezza guidance to $2.825–$2.875B and the Soleno acquisition integration remain key drivers. Watch for further pipeline updates and the next earnings call for sustained momentum.
At the time of this announcement, NBIX was trading at $167.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.8B. The 52-week trading range was $122.14 to $186.12. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.